CD56 Antigen

"CD56 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.

Descriptor ID	D019002
MeSH Number(s)	D12.776.395.550.200.250.520.156 D12.776.543.550.200.250.520.156 D23.050.301.264.894.156 D23.050.301.350.250.520.156 D23.101.100.894.156
Concept/Terms	CD56 Antigen CD56 Antigen Antigen, CD56 Leu-19 Antigen Antigen, Leu-19 Leu 19 Antigen Antigens, CD56 NKH-1 Antigen Antigen, NKH-1 NKH 1 Antigen CD56 Antigens

Below are MeSH descriptors whose meaning is more general than "CD56 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
Cell Adhesion Molecules [D12.776.395.550.200]
Cell Adhesion Molecules, Neuronal [D12.776.395.550.200.250]
Neural Cell Adhesion Molecules [D12.776.395.550.200.250.520]
CD56 Antigen [D12.776.395.550.200.250.520.156]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
Cell Adhesion Molecules [D12.776.543.550.200]
Cell Adhesion Molecules, Neuronal [D12.776.543.550.200.250]
Neural Cell Adhesion Molecules [D12.776.543.550.200.250.520]
CD56 Antigen [D12.776.543.550.200.250.520.156]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
CD56 Antigen [D23.050.301.264.894.156]
Cell Adhesion Molecules [D23.050.301.350]
Cell Adhesion Molecules, Neuronal [D23.050.301.350.250]
Neural Cell Adhesion Molecules [D23.050.301.350.250.520]
CD56 Antigen [D23.050.301.350.250.520.156]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
CD56 Antigen [D23.101.100.894.156]

Below are MeSH descriptors whose meaning is more specific than "CD56 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CD56 Antigen" by people in this website by year, and whether "CD56 Antigen" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 3 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2008	1	2	3
2014	1	0	1
2017	0	1	1
2018	1	0	1
2019	0	1	1
2020	0	2	2
2021	1	0	1

Below are the most recent publications written about "CD56 Antigen" by people in Profiles.

Madahian S, Judelson R, Zhu X, Meng X, Dresser K, Hutchinson L, Bledsoe JR. CD56 expression in basaloid anal squamous cell carcinoma - A potential diagnostic pitfall. Ann Diagn Pathol. 2021 Aug; 53:151758.

View in: PubMed
Kim IE, Amin A, Wang LJ, Cheng L, Perrino CM. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):687-693.

View in: PubMed
Forconi CS, Oduor CI, Oluoch PO, Ong'echa JM, M?nz C, Bailey JA, Moormann AM. A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases. Front Cell Infect Microbiol. 2020; 10:162.

View in: PubMed
Matsuda M, Ono R, Iyoda T, Endo T, Iwasaki M, Tomizawa-Murasawa M, Saito Y, Kaneko A, Shimizu K, Yamada D, Ogonuki N, Watanabe T, Nakayama M, Koseki Y, Kezuka-Shiotani F, Hasegawa T, Yabe H, Kato S, Ogura A, Shultz LD, Ohara O, Taniguchi M, Koseki H, Fujii SI, Ishikawa F. Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice. Life Sci Alliance. 2019 04; 2(2).

View in: PubMed
Forconi CS, Cosgrove CP, Saikumar-Lakshmi P, Nixon CE, Foley J, Ong'echa JM, Otieno JA, Alter G, M?nz C, Moormann AM. Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas. Blood Adv. 2018 05 22; 2(10):1101-1114.

View in: PubMed
Frese CK, Mikhaylova M, Stucchi R, Gautier V, Liu Q, Mohammed S, Heck AJR, Altelaar AFM, Hoogenraad CC. Quantitative Map of Proteome Dynamics during Neuronal Differentiation. Cell Rep. 2017 02 07; 18(6):1527-1542.

View in: PubMed
Freeman CM, Stolberg VR, Crudgington S, Martinez FJ, Han MK, Chensue SW, Arenberg DA, Meldrum CA, McCloskey L, Curtis JL. Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. PLoS One. 2014; 9(7):e103840.

View in: PubMed
Pozdnyakova O, Morgan EA, Li B, Shahsafaei A, Dorfman DM. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma. Leuk Lymphoma. 2012 Oct; 53(10):1905-10.

View in: PubMed
Waziri A, Killory B, Ogden AT, Canoll P, Anderson RC, Kent SC, Anderson DE, Bruce JN. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol. 2008 Jun 01; 180(11):7673-80.

View in: PubMed
Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008 Jul; 81(1):65-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals